Ask AI
ProCE Banner Activity

Decera: 全球智慧,造福本土:生物标志物在阿尔茨海默病诊疗中的实用整合路径

PDF

血液生物标志物 (BBM) 为阿尔茨海默病早期检测和诊断提供了一种变革性工具,作为 PET 和脑脊液检测的非侵入性且经济高效的替代方案。国际阿尔茨海默病专家就如何将 BBM 评估融入临床实践提供了见解,包括考虑医疗保健路径、准入机制和文化期望方面的区域差异。本次圆桌网络研讨会的幻灯片和文字记录还提供西班牙语、普通话、日语、意大利语和德语版本。

Released: July 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for global primary care physicians, general practitioners, general neurologists, nurse practitioners, physician associates, and other healthcare professionals caring for patients at risk of developing Alzheimer’s Disease. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Learning Objective 1: 评估血液生物标志物临床效用的新证据,以促进阿尔茨海默病的及时准确诊断。

  • Learning Objective 2: 识别适合接受血液生物标志物检测的患者,以支持制定个体化的诊疗路径。

  • Learning Objective 3: 在阿尔茨海默病的全病程管理中,应用循证策略和生物标志物检测相关临床指引,指导临床决策与转诊。

Financial Disclosures

Primary Author

Atsushi Iwata, MD, PhD: consultant/advisor/speaker: Biogen, Eisai, Fujirebio, Janssen, Kowa, Lilly, MSD, Otsuka, Sony, Sysmex, UCB.

Sebastian Palmqvist, MD, PhD: consultant/advisor/speaker: BioArctic, Danaher, Eisai, Lilly, Novo Nordisk, Roche, Sanofi.

Jiong Shi, MD, PhD, FAAN, has no relevant financial relationships to disclose.

Raymond Scott Turner, PhD, MD, FANA, FAAN: researcher (paid to institution): Cognition Therapeutics, Eisai, Lilly; consultant/advisor/speaker: Lilly.